The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness

Author(s): Zanchetti A, Rosei EA, Dal Palù C, Leonetti G, Magnani B, et al.


Background: It is unclear whether the carotid intima-media thickness can be influenced by antihypertensive treatment and whether some antihypertensive agents, such as calcium antagonists, may have a greater effect on this parameter than others, such as diuretics. The present paper reports the principal results of the ultrasound substudy of the randomized, prospective, controlled, Verapamil in Hypertension and Atherosclerosis Study (VHAS).

Design and methods: In 498 hypertensive patients in eight Italian centres, randomized to either verapamil (240 mg once a day) or chlorthalidone (25 mg once a day), a B-mode ultrasound scan was performed according to a standardized procedure at baseline and after 3, 12, 24, 36 and 48 months of treatment. The maximum intima-media thicknesses of the far walls of common, bifurcation and internal carotid arteries were measured bilaterally, and the following indices calculated: the mean thickness at the six measured sites, the mean thickness at the common and bifurcation sites and the single maximum thickness. The primary endpoint for treatment efficacy was the slope of the change over 4 years (rate of change, mm/year), corrected by using the initial mean over the six sites (baseline + 3 months) as a covariate (mm/year per mm). The patients were also classified into three strata according to their baseline single maximum thickness: those with normal carotid arteries (single maximum ( 1 mm), those with thickened carotid arteries (single maximum > 1 and < or = 1.5 mm and those with carotid plaques (single maximum > 1.5 mm).

Results: Among the 456 patients with satisfactory baseline ultrasound readings, 33% were classified with normal carotid arteries, 27% with thickened carotid arteries and 40% with plaques. In the intention-to-treat population (377 patients with ultrasound measurements taken on at least three different occasions over a period of at least 2 years), the rate of change in the mean thickness at the six sites measured was rather small (0.015 mm/year), but significantly (P < 0.05) smaller in patients with plaques (0.003 mm/year) than in patients with thickened or with normal carotids (0.023 and 0.025 mm/year, respectively). When related to initial values, the rate of change in the mean thickness at the six sites had a negative slope (-0.059 mm/year per mm, P < 0.01). Although rates of change in the carotid intima-media thickness in unstratified patients were not different in those treated with verapamil or with chlorthalidone, when changes in the mean thickness of six sites were related to the initial value, the slope of this relationship was significantly different in the two treatment groups (verapamil -0.082 versus chlorthalidone -0.037 mm/year per mm, P < 0.02). The blood pressure-lowering effect of the two randomized treatments was similar. Taking fatal and nonfatal, major and minor cardiovascular events together, there were 19 events in the verapamil group and 35 in the chlorthalidone group, with a significantly (P < 0.01) greater incidence in patients with plaques, and among patients with plaques in those who were randomized to chlorthalidone (P < 0.05).

Conclusions: In accord with evidence from animal models of atherosclerosis, the calcium antagonist verapamil was more effective than the diuretic chlorthalidone in promoting regression of thicker carotid lesions. Changes in the carotid intima-media thickness were small in both groups, and the differences between the changes under the two treatments were consequently small, but the observation that these small differences in carotid wall changes were paralleled by differences in the incidence of cardiovascular events (better intima-media thickness regression with verapamil paralleled by a lower cardiovascular event rate) suggests that even small effects on carotid plaques may have clinical and prognostic relevance.

Similar Articles

LDL cholesterol: the lower the better

Author(s): Martin SS, Blumenthal RS, Miller M

High density lipoproteins and atherosclerosis: emerging aspects

Author(s): Sala F, Catapano AL, Norata GD

High-density lipoprotein function, dysfunction, and reverse cholesterol transport

Author(s): Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD

Targeting Innate Immunity for CV Benefit

Author(s): Moore KJ, Freeman MW

Blood serum atherogenicity associated with coronary atherosclerosis

Author(s): Orekhov AN, Tertov VV, Pokrovsky SN, Adamova IYu, Martsenyuk ON, et al.

Characteristics of low density lipoprotein isolated from circulating immune complexes

Author(s): Tertov VV, Sobenin IA, Orekhov AN, Jaakkola O, Solakivi T, et al.

Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein

Author(s): Tertov VV, Kaplun VV, Sobenin IA, Boytsova EY, Bovin NV, et al.

Presence of a modified low density lipoprotein in humans

Author(s): Avogaro P, Bon GB, Cazzolato G

Autoantibodies against modified low density lipoprotein

Author(s): Orekhov AN, Tertov VV, Kabakov AE, Adamova IYu, Pokrovsky SN, et al.

Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis

Author(s): Tertov VV, Orekhov AN, Kacharava AG, Sobenin IA, Perova NV, et al.

Lipoprotein immune complexes as markers of atherosclerosis

Author(s): Orekhov AN, Kalenich OS, Tertov VV, Novikov ID

Diagnostic value of immune cholesterol as a marker for atherosclerosis

Author(s): Orekhov AN, Kalenich OS, Tertov VV, Perova NV, Novikov IyD, et al.

Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis

Author(s): Sobenin IA, Karagodin VP, Melnichenko AC, Bobryshev YV, Orekhov AN

Pluronic block copolymers inhibit low density lipoprotein self-association

Author(s): Melnichenko AA, Aksenov DV, Myasoedova VA, Panasenko OM, Yaroslavov AA, et al.

Three-dimensional cytoarchitecture of normal and atherosclerotic intima of human aorta

Author(s): Rekhter MD, Andreeva ER, Mironov AA, Orekhov AN

Primary cultures of enzyme-isolated cells from normal and atherosclerotic human aorta

Author(s): Orekhov AN, Andreeva ER, Krushinsky AV, Smirnov VN

Lipids in cells of atherosclerotic and uninvolved human aorta

Author(s): Orekhov AN, Tertov VV, Novikov ID, Krushinsky AV, Andreeva ER, et al.

Adult human aortic cells in primary culture: heterogeneity in shape

Author(s): Orekhov AN, Krushinsky AV, Andreeva ER, Repin VS, Smirnov VN

Cell proliferation in normal and atherosclerotic human aorta

Author(s): Orekhov AN, Kosykh VA, Repin VS, Smirnov VN

Primary culture of human aortic intima cells as a model for testing anti-atherosclerotic drugs

Author(s): Orekhov AN, Tertov VV, Kudryashov SA, Khashimov KhA, Smirnov VN

Atherogenicity of blood serum from patients with coronary heart disease

Author(s): Chazov EI, Tertov VV, Orekhov AN, Lyakishev AA, Perova NV, et al.

Antiatherosclerotic effects of calcium antagonists

Author(s): Orekhov AN, Baldenkov GN, Tertov VV, Ruda MYa, Khashimov KA, et al.

Effects of garlic on atherosclerosis

Author(s): Orekhov AN, Grünwald J

Anti-atherosclerotic therapy based on botanicals

Author(s): Orekhov AN, Sobenin IA, Korneev NV, Kirichenko TV, Myasoedova VA, et al.

The antiatherosclerotic effect of Allium sativum

Author(s): Koscielny J, Klüssendorf D, Latza R, Schmitt R, Radtke H, et al.

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) Am J Cardiol 75: 455-459

Author(s): Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, et al.

Kuopio Atherosclerosis Prevention Study (KAPS)

Author(s): Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, et al.

Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events

Author(s): Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, et al.

Beneficial effects of colestipol-niacin therapy on the common carotid artery

Author(s): Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu CR, et al.

Coronary angiographic changes with lovastatin therapy

Author(s): Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, et al.

Carotid plaque morphologic characteristics

Author(s): Aidinian G, Weiswasser JM, Arora S, Abularrage CJ, Singh N, et al.

Thematic review series: The immune system and atherogenesis

Author(s): Daugherty A, Webb NR, Rateri DL, King VL

Evidence-based assessment of the impact of the WHI on women's health

Author(s): Burger HG, MacLennan AH, Huang KE, Castelo-Branco C